DCT and cancer: Although this treatment did not correct the expansion defect of WT Trp2/Kb-specific cells in a selective manner, it did improve their numbers to the level seen among untreated Dct-/- cells, supporting the use of IL-2R-directed therapies in cancer immunotherapy designed to engage tolerant cells (Moynihan et al., 2016; Rosenberg, 2014; Waithman et al., 2008).